The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Michael Roche; Laura Parisi; Linda Li; Amy Knehans; Rebecca Phaeton; Joshua P. Kesterson

doi:10.4081/oncol.2018.346

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Michael Roche, Laura Parisi, Linda Li, Amy Knehans, Rebecca Phaeton, Joshua P. Kesterson

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta^{T M}) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

Original language	English (US)
Pages (from-to)	8-13
Number of pages	6
Journal	Oncology Reviews
Volume	12
Issue number	1
DOIs	https://doi.org/10.4081/oncol.2018.346
State	Published - Jan 30 2018

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.4081/oncol.2018.346

Cite this

@article{aef15a6a200d4d62aec7281d1053f47a,

title = "The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review",

abstract = "Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.",

author = "Michael Roche and Laura Parisi and Linda Li and Amy Knehans and Rebecca Phaeton and Kesterson, {Joshua P.}",

note = "Publisher Copyright: {\textcopyright} CopyrightM. Roche et al, 2018.",

year = "2018",

month = jan,

day = "30",

doi = "10.4081/oncol.2018.346",

language = "English (US)",

volume = "12",

pages = "8--13",

journal = "Oncology Reviews",

issn = "1970-5557",

publisher = "Frontiers Media SA",

number = "1",

}

TY - JOUR

T1 - The role of pemetrexed in recurrent epithelial ovarian cancer

T2 - A scoping review

AU - Roche, Michael

AU - Parisi, Laura

AU - Li, Linda

AU - Knehans, Amy

AU - Phaeton, Rebecca

AU - Kesterson, Joshua P.

N1 - Publisher Copyright: © CopyrightM. Roche et al, 2018.

PY - 2018/1/30

Y1 - 2018/1/30

N2 - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

AB - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85049181480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049181480&partnerID=8YFLogxK

U2 - 10.4081/oncol.2018.346

DO - 10.4081/oncol.2018.346

M3 - Review article

C2 - 29983902

AN - SCOPUS:85049181480

SN - 1970-5557

VL - 12

SP - 8

EP - 13

JO - Oncology Reviews

JF - Oncology Reviews

IS - 1

ER -

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this